A prospective Phase III trial evaluating patient self-reported pain and cosmesis in accelerated partial breast irradiation utilizing 3-D versus intensity-modulated radiotherapy

Charles E Leonard, Yunfei Wang, Lina Asmar, Rachel Y Lei, Kathryn T Howell, Phyllis L Henkenberns, Timothy K Johnson, Tracy L Hobart, Shannon P Tole, Jane M Kercher, Jodi L Widner, Lora Barke, Terese Kaske, Dennis L Carter, Charles E Leonard, Yunfei Wang, Lina Asmar, Rachel Y Lei, Kathryn T Howell, Phyllis L Henkenberns, Timothy K Johnson, Tracy L Hobart, Shannon P Tole, Jane M Kercher, Jodi L Widner, Lora Barke, Terese Kaske, Dennis L Carter

Abstract

Purpose/objective: The primary objective is to examine patient self-assessment of breast pain and cosmesis between three-dimensional (3D-CRT) versus intensity-modulated radiotherapy (IMRT). The secondary objective is to evaluate any relationship of treatment planning conformality of both cohorts to patient-assessed pain. Assessments were performed at interim 12, 24, 36, and 48 months with a final 5-year assessment.

Materials/methods: In total, 656 patients (3D-CRT n = 328; IMRT n = 328) were randomly assigned to either IMRT or 3D-CRT accelerated partial breast radiotherapy to 38.5 Gy in 10 BID 3.85 Gy fractions.

Results: Median follow-up was 3 years. Multivariate analysis showed that pain severity significantly decreased from baseline to the 12-month follow-up visit (<0.001 for both 3D-CRT and IMRT) in each cohort. There was significantly less pain at 2 (p = 0.002) and 3 years (0.045) in the IMRT arm versus the 3D-CRT arm when compared to the baseline pain level. There was no difference in patient-assessed cosmesis at any follow-up point; however, although MD-assessed cosmesis showed no difference from years 1 to 4, there was significantly better cosmesis for 3D-CRT versus IMRT (p = 0.047) at 5 years. There was a significant correlation between a maximum pain score and an increase in the CI100 (indicating less conformity) in the IMRT cohort (p < 0.01) and in the IMRT subgroup when the CI100 was ≤0.37 cohort arm (p = 0.01).

Conclusion: In the analysis of our primary objective we found that at 2 years, IMRT resulted in more interval improvement in breast pain after baseline when compared to patients treated with 3D-CRT planning. As seen in our secondary analysis, this may be due to the ability of IMRT to achieve higher conformality (as evidenced by lower CI values) resulting in less fibrosis. There were no differences in patient-assessed cosmesis or MD-assessed cosmesis for years 1-4; however, physician-assessed 5-year cosmesis was better with 3D-CRT.

Trial registration: ClinicalTrials.gov NCT01185132 NCT01185145.

Keywords: accelerated partial breast; breast cancer; radiotherapy.

Conflict of interest statement

None.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier estimation of overall survival

References

    1. Veronesi U, Cascinelli N, Mariani L, et al. Twenty‐year follow‐up of a randomized study comparing breast‐conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227‐1232. doi:10.1056/nejmoa020989
    1. Fisher B, Anderson S, Bryant J, et al. Twenty‐year follow‐up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233‐1241. doi:10.1056/nejmoa022152
    1. Bijker N, Meijnen P, Peterse JL, et al. Breast‐conserving treatment with or without radiotherapy in ductal carcinoma‐in‐situ: ten‐year results of European Organisation for research and treatment of cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381‐3387. doi:10.1200/jco.2006.06.1366
    1. Solin LJ, Fourquet A, Vicini FA, et al. Long‐term outcome after breast‐conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103(6):1137‐1146. doi:10.1002/cncr.20886
    1. Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST‐Forward): 5‐year efficacy and late normal tissue effects results from a multicentre, non‐inferiority, randomised, phase 3 trial. The Lancet. 2020;395(10237):1613‐1626. doi:10.1016/S0140-6736(20)30932-6
    1. Gilligan MA, Kneusel RT, Hoffmann RG, et al. Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med Care. 2002;40(3):181‐189. doi:10.1097/00005650-200203000-0002
    1. Nattinger AB, Kneusel RT, Hoffmann RG, et al. Relationship of distance from a radiotherapy facility and initial breast cancer treatment. J Natl Cancer Inst. 2001;93(17):1344‐1346. doi:10.1093/jncvi/93.17.1344
    1. Nattinger AB, Hoffmann RG, Kneusel RT, et al. Relation between appropriateness of primary therapy for earlystage breast carcinoma and increased use of breast‐conserving surgery. Lancet. 2000;356(9236):1148‐1153. doi:10.1016/s0140-6736(00)02757-4
    1. Offersen BV, Overgaard M, Kroman N, et al. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systemic review. Radiother Oncol. 2009;90(1):1‐13. doi:10.1016/j.radonc.2008.08.005
    1. NSABP B‐39/RTOG 0413 protocol. . Accessed 9 Jan 2013.
    1. Pashtan IM, Recht A, Ancukiewicz M, et al. External beam accelerated partial‐breast irradiation using 32 Gy in 8 twice‐daily fractions: 5‐year results of a prospective study. Int J Radiat Oncol Biol Phys. 2012;84(3):e271‐e277. doi:10.1016/j.ijrobp.2012.04.019
    1. Taghian AG, Alm El‐Din M, Smith BL, et al. Interim results of a phase I/II trial of 3D‐conformal external beam accelerate partial breast irradiation in patients with early breast cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):S4. 10.1016/j.ijrobp.2008.06.776
    1. Formenti SC, Hsu H, Fenton‐Kerimian M, et al. Prone accelerated partial breast irradiation after breast‐conserving surgery: five‐year results of 100 patients. Int J Radiat Oncol Biol Phys. 2012;84(3):606‐611. doi:10.1016/j.jirobp.2012.039
    1. Vicini F, Winter K, Wong J, et al. Initial efficacy results of RTOG 0319: three‐dimensional conformal radiation therapy (3D‐CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77(4):1120‐1127. doi:10.1016/j.ijrobp.2009.06.067
    1. Shah C, Wilkinson JB, Lanni T, et al. Five‐year outcomes and toxicities using 3‐dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Clin Breast Cancer. 2013;13(3):206‐211. doi:10.1016/j.clbc.2012.09.020
    1. Chen PY, Wallace M, Mitchell C, et al. Four‐year efficacy, cosmesis, and toxicity using three‐dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(4):991‐997. doi:10.1016/j.ijrobp.2009.03.012
    1. Julian TB, Constantino JP, Vicini FA, et al. Early toxicity results with 3 conformal external beam therapy (CEBT) from the NSABP B‐39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. J Clin Oncol. 2011;29(15_suppl):101131011. doi:10.1200/jco.2011.29.15_suppl.1011
    1. Berrang TS, Olivotto I, Kim D‐H, et al. Three‐year outcomes of a canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81(5):1220‐1227. doi:10.1016/j.ijrobp.2010.07.2003
    1. Whelan TJ, Olivotto I, Parpia S, et al. Interim toxicity results from RAPID: a randomized trial of Accelerated Partial Breast Irradiation (APBI) using 3D Conformal External Beam Radiation Therapy (3D CRT). Int J Radiat Oncol Biol Phys. 2013;85(1):21‐22. doi:10.1016/j.ijrobp.2012.11.015
    1. Leonard KL, Hepel JT, Hiatt JR, Dipetrillo TA, Price LL, Wazer DE. The effect of dose‐volume parameters and intrafraction interval on cosmetic outcome and toxicity after 3‐dimensional conformal accelerated breast irradiation. Int J Radiat Oncol Biol Phys. 2013;85(3):623‐629. doi:10.1016/j.ijrobp.2012.06.052
    1. Lewin AA, Derhagopian R, Saigal K, et al. Accelerated partial breast irradiation is safe and effective using intensity‐modulated radiation therapy in selected early‐stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(5):2014‐21001. doi:10.1016/j.ijrobp.2011.02.024
    1. Jagsi R, Ben‐David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity‐modulated radiotherapy with active breathing control for accelerated partial‐breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(1):71‐78. doi:10.1016/k.ijrobp.2009.01.041
    1. Livi L, Buonamici FB, Simontacchi G, et al. Accelerated partial breast irradiation with IMRT: mew technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial. Int J Radiat Oncol Biol Phys. 2010;77(2):509‐515. doi:10.1016/j.ijobp.2011.02.024
    1. Leonard C, Carter D, Kercher J, et al. Prospective trial of accelerated partial breast intensity‐modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1291‐1298. doi:10.1016/j.ijrobp.2006.11.016
    1. Leonard CE, Tallhamer M, Johnson T, et al. Clinical experience with image‐guided radiotherapy in an accelerated partial breast intensity‐modulated radiotherapy protocol. Int J Radiat Oncol Biol Phys. 2010;76:234‐528. doi:10.1016/j.ijrobp.2009.02.001
    1. Rusthoven KE, Carter DL, Howell K, et al. Accelerated partial‐breast intensity‐modulated radiotherapy results in improved dose distribution when compared with three‐dimensional treatment‐planning techniques. Int J Radiat Oncol Biol Phys. 2008;70(1):296‐302. doi:10.1016/j.ijrobp.2007.08.047
    1. Reeder R, Carter DL, Howell K, et al. Predictors for clinical outcomes after accelerated partial breast intensity‐modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2009;74(1):92‐97. doi:10.1016/j.ijrpbp.2008.06.1917
    1. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987‐1001. doi:10.1016/j.ijrobp.2009.02.031
    1. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three‐dimensional conformal radiotherapy and intensity‐modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124‐1129. doi:10.1016/j.ijrobp.2007.11.044
    1. Sharma NK, Li T, Chen DY, et al. Intensity‐modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Onocol Biol Phys. 2011;80(2):437‐444. doi:10.1016/j.ijrobp.2010.02.040
    1. Sheets NC, Goldin GH, Meyer AM, et al. Intensity‐modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611. doi:10.1001/jama.2012.460
    1. Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity‐modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26(13):2085‐2092. doi:10.1200/jco.2007.15.2488
    1. Barnett GC, Wilkinson J, Moody AM, et al. A randomized controlled trial of forward‐planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. Radiother Oncol. 2009;92(1):34‐41. doi:10.1016/j.radonc.2009.03.003
    1. Hardee ME, Raza S, Becker SJ, et al. Prone hypofractionated whole‐breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. Int J Radiat Oncol Biol Phys. 2012;82(3):e415‐e423. doi:10.1016/j.ijrobp.2011.06.1950
    1. Freedman GM, Li T, Nicolaou N, et al. Breast intensity‐modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Oncol Biol Phys. 2009;74(3):689‐694. doi:10.1016/j.ijrobp.2008.08.071
    1. McDonald MW, Godette KD, Butker EK, et al. Long‐term outcomes of IMRT for breast cancer: a single‐institution cohort analysis. Int J Radiat Oncol Biol Phys. 2008;72(4):1031‐1040. doi:10.1016/j.ijrobp.2008.02.053
    1. Harsolia A, Kestin L, Grills I, et al. Intensity‐modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge‐base breast radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(5):1375‐1380. doi:10.1016/j.ijrobp.2007.02.044
    1. Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three‐dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75(5):1290‐1296. doi:10.1016/j.ijrobp.2009.01.009
    1. Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from rapid: a randomized trial of accelerated partial breast irradiation using three‐dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31(32):4038‐4045. doi:10.1200/joc.2013.50.5511
    1. Peterson D, Troung PT, Olivito PS, et al. Predictors of adverse cosmetic outcome in the RAPIC trial: an exploratory analysis. Int J Radiat Oncol Biol Phys. 2015;91(5):968‐976. doi:10.1016/j.ijrobp.2014.12.040
    1. Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity‐modulated radiotherapy versus whole breast irradiation: 5‐year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51(4):451‐463. doi:10.1016/j.ejca.2014.12.013

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner